Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Smart Patch Delivers Anticoagulants in Response to Blood Thrombin Levels

XTALKS VITALS NEWS

Blood

While heparin is an effective blood thinner, the dosing must be optimized to prevent patients from spontaneous hemorrhaging.

Share this!

November 30, 2016 | by Sarah Hand, M.Sc.

Patients with thrombosis – a condition which makes a person more prone to blood clots – must regularly monitor their blood and administer anticoagulant drugs, when needed. Now, researchers at North Carolina State University (NC State) and the University of North Carolina (UNC) at Chapel Hill, have developed a smart sensing patch which can automatically release blood thinners – such as heparin – in response to rising blood clotting factor levels.

Blood clots in the body can cause dangerous health conditions such as heart attack, stroke or a pulmonary embolism. While heparin is an effective blood thinner, the dosing must be optimized to prevent patients from spontaneous hemorrhaging.

“Our goal was to generate a patch that can monitor a patient's blood and release additional drugs when necessary; effectively, a self-regulating system,” said Zhen Gu, associate professor in the joint biomedical engineering program at NC State and UNC, and co-corresponding author on a paper describing the work. The research was published in the journal, Advanced Material.



The patch consists of polymer microneedles impregnated with hyaluronic acid (HA) and heparin. The smart patch is sensitive to levels of thrombin, which activates the clotting response in the blood. When the polymer patch senses elevated thrombin levels in the blood, the enzyme signals the release of heparin into the bloodstream.

“The more thrombin there is in the bloodstream, the more heparin is needed to reduce clotting,” said Yuqi Zhang, a Ph.D. student in Gu's lab and one of the lead authors on the publication. “So we created a disposable patch in which the more thrombin there is in the blood stream, the more heparin is released.”

So far, the patch has only been tested in a mouse model where the animals were injected with a fatal dose of thrombin. To compare the patch’s effectiveness with a heparin shot, the mice were assigned to one of three groups: heparin injection, heparin smart patch or no treatment. Only those mice who received no treatment died as a result of blood clotting in the lungs after the thrombin injection.

The surviving mice were then re-injected with another dose of thrombin six hours after receiving treatment. At 15 minutes post-thrombin injection, 80 percent of the mice that received a heparin shot alone had died, while all of the mice with the heparin patch were stable.

“We're excited about the possibility of using a closed-loop, self-regulating smart patch to help treat a condition that affects thousands of people every year, while hopefully also driving down treatment costs,” said Gu. “This paper represents a good first step, and we're now looking for funding to perform additional preclinical testing.”


Keywords: Anticoagulant, Blood Clot, Preclinical


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Use of Testosterone Treatments Boosted by DTC Ad Campaigns

March 24, 2017 - Those with a stake in the pharmaceutical industry often question the effectiveness of direct-to-consumer (DTC) advertising, and whether it truly influences consumers to talk to their doctors about medical conditions and perhaps even ask for drugs by name.

Featured In: Pharmaceutical Marketing News


FDA Approves New Drug for Parkinson’s Disease

March 23, 2017 - Newron Pharmaceuticals’ Xadago (safinamide) has been approved by the US Food and Drug Administration (FDA) as an add-on medication for patients with Parkinson’s disease.

Featured In: Clinical Trials News, Life Science News, Pharmaceutical News


Amgen Identifies Issue with Patient Access to PCSK9 Inhibitor

March 23, 2017 - Most US patients hoping to get their PCSK9 inhibitor medications covered by their prescription drug plan are being denied, according to two new studied conducted by Amgen.

Featured In: Biotech News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?

REGISTER FOR THESE WEBINARS

How to Improve the Speed and Efficiency of Your Clinical Trials


High Performance Computing for High Content Screening - A Case Study


The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review


Treatment of Psoriasis: Improvements Through Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.